Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Speedy Vaccine Production Among Goals Of FDA's Budget Proposal For Countermeasures

Executive Summary

FDA plans to expand its medical countermeasures program beyond pandemic influenza with the infusion of $70 million requested in the fiscal year 2012 budget sent to Capitol Hill by the Obama Administration Feb. 14.
Advertisement

Related Content

Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA's Revised Strategic Plan Emphasizes Countermeasures, Biosimilars
FDA's Hamburg Says Japanese Crisis Shows Need To Fund Countermeasure Development
FDA FY 2012 Budget Gives Hamburg Regulatory Science Upgrade A Year Late
FDA FY 2012 Budget Gives Hamburg Regulatory Science Upgrade A Year Late
FDA FY 2012 Budget Gives Hamburg Regulatory Science Upgrade A Year Late
FDA Regulatory Science Gets The Flu (Funding) In HHS Overhaul Of Bioterror Product Development

Topics

Advertisement
UsernamePublicRestriction

Register

PS053151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel